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Abstract
Introduction: This study investigated the use of eucapnic voluntary hyperpnea 
(EVH) to monitor efficacy of pharmacological therapy in elite swimmers with 
exercise- induced bronchoconstriction (EIB). Secondly, it evaluated the long- term 
test- retest repeatability of EVH in this population.
Methods: Twenty- seven elite international swimmers were included in this retro-
spective analysis of comprehensive respiratory assessments. Following an initial 
“withheld- therapy” assessment, athletes with EIB had been prescribed appropriate 
pharmacological therapy and returned twelve months later for a follow- up assess-
ment to monitor EIB protection afforded by treatment. EIB- negative athletes had 
returned to confirm initial diagnosis, as were still reporting persistent respiratory 
symptoms. Athletes were retrospectively grouped into either “Therapy Adherent 
Group” (n  =  12) or “Repeatability Group” (discontinued therapy at follow- up or 
EIB- negative, n = 15).
Results: Greatest fall in forced expiratory volume in 1  second (ΔFEV1max) was 
significantly lower following therapy adherence (−11.8 ± 3.8%) compared to ini-
tial assessment (−24.0 ± 11.3%; P <  .01). “Repeatability Group” ΔFEV1max did 
not differ significantly between initial assessment (−13.1  ±  4.5%) and follow- up 
(−12.3 ± 5.6%; P = .32), and showed good agreement (0.6%; −5.9%, 7.1%).
Conclusion: A follow- up assessment utilizing EVH is useful in the management of 
EIB and shows good test- retest repeatability over twelve months in elite swimmers 
who discontinue treatment or are EIB- negative.
K E Y W O R D S
asthma therapy, elite athletes, reproducibility, test- retest repeatability
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1 |  INTRODUCTION
Exercise- induced bronchoconstriction (EIB) is a transient 
airway disorder triggered by intense exercise stimuli.1 By 
some, EIB could be considered an “occupational airway dis-
order” for elite athletes.2 Prevalence is reported to be sport 
specific, with up to two- thirds of athletes demonstrating ob-
jective evidence of EIB in some sports.3,4 Particularly at risk 
are elite swimmers, winter sports, and endurance athletes that 
require repeated exposure to high minute ventilation in asth-
mogenic environments (ie, cold dry- air, areas of high pollen, 
and pollution).3- 5
Elite swimming provides a unique training and compe-
tition environment, as athletes are exposed to additional 
chlorination by- products.3 Although highly specific, it can 
be difficult to adequately control a field- based exercise chal-
lenge to induce bronchoconstriction in elite swimmers. The 
inability to standardize protocol exercise intensity, minute 
ventilation, and environmental conditions can all contrib-
ute to poor EIB detection and add additional training load 
in this population.5- 7 The lack of standardization is prob-
lematic when reassessing athletes or monitoring efficacy of 
pharmacological therapy. While there is no “gold standard” 
assessment for EIB,8 the American Thoracic Society (ATS) 
suggests an indirect bronchoprovocation assessment, the eu-
capnic voluntary hyperpnea (EVH) challenge, as a suitable 
surrogate for exercise.9 The EVH has a high level of sensi-
tivity and the ability to induce the pathogenic mechanisms 
associated with EIB.5,10,11
Our research group has previously demonstrated that EVH 
can provide objective evidence to support diagnosis of EIB in 
elite athletes.3,4,12 It is not uncommon for athletes with EIB to 
demonstrate enhanced pulmonary function at baseline13 and 
still report respiratory symptoms following treatment.12,14 
Therefore, when reviewing the efficacy of initiation or alter-
ation in pharmacological therapy, one should incorporate the 
same indirect airway assessment used to support the initial 
diagnosis.
EVH has previously been used to objectively evaluate 
bronchoconstriction following specific acute pharmacolog-
ical,15- 18 and short- term non- pharmacological therapy (eg, 
prebiotics).19 Jackson et al12 demonstrated EVH can be used 
to assess EIB severity following nine weeks of individualized 
pharmacological therapy in elite football players. Therefore, 
it may be suitable to use EVH to monitor EIB management 
over a longer time period (eg, at an annual assessment). 
Moreover, further research is required to investigate the util-
ity of EVH to monitor EIB management in other elite sports, 
such as a swimming population, where athletes are exposed 
to additional asthmogenic stimuli.3,6,20
For EVH to be suitable for monitoring efficacy of EIB 
therapy, it requires good test- retest repeatability.21 EVH has 
previously shown good short- (≤7 days), and medium- term 
(≤70  days) test- retest repeatability in elite and recreational 
athletes.22- 24 However, the repeatability of EVH on an annual 
basis, and when used within an athlete's annual medical as-
sessment, has not been reported.
The primary aim of this research was to investigate the 
use of EVH to annually monitor the efficacy of individual-
ized pharmacological therapy for EIB in elite swimmers. The 
secondary aim was to evaluate the long- term test- retest re-
peatability of EVH in elite swimmers who had discontinued 
therapy or without EIB diagnosis but persistent symptoms.
2 |  METHODS
2.1 | Study overview
This study involved retrospective analysis of data collected 
from a subsection of the British Swimming Team at an-
nual medical assessments between 2017 and 2019. Sixty- 
three swimmers were assessed during this period. However, 
twenty- seven athletes had multiple assessments during this 
time due to receiving pharmacological intervention or having 
persistent respiratory symptoms. In brief, athletes presented 
in this study initially underwent a comprehensive respiratory 
assessment, then twelve months later returned for a follow- up 
assessment to monitor EIB protection afforded by therapy, 
or to confirm a negative test. The study was approved by the 
University of Kent School of Sport and Exercise Sciences 
Research Ethics Committee (Prop 86_2018_19). All partici-
pants provided written informed consent to anonymized data 
analysis.
2.2 | Initial respiratory assessment
Prior to the initial assessment, all participants were asked 
to withhold use of any previously prescribed EIB or asthma 
medication to determine baseline EIB severity. Most notably, 
short- acting β2- agonists (SABA) were withheld for at least 
8  hours, inhaled corticosteroids (ICS) for 24  hours, long- 
acting β2- agonists (LABA) for 24 hours, and leukotriene re-
ceptor antagonists (LTRA) for 96 hours. Athletes were also 
asked to avoid caffeine and exercise for ≥4 hours before as-
sessments in accordance with EVH guidelines.25
Airway inflammation was assessed via fraction of exhaled 
nitric oxide (FeNO) at a flow rate of 50 mL s−1 against 16cmH2O 
of resistance (NIOX VERO, NIOX, Aerocrine, Sweden) in 
accordance with ATS recommendations.26 Participants then 
completed baseline maximal flow- volume maneuvers in trip-
licate using a turbine  transducer spirometer (Spiro  USB, 
Micro Medical LTD, Rochester, UK). Predicted values were 
calculated using the equations of Kuster et al27 Within and be-
tween maneuver criteria were met in accordance to ATS/ERS 
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guidelines.28 Participants then completed an EVH challenge; 
inhaling medical- grade dry- air at a target ventilation rate of 85% 
predicted maximum voluntary ventilation (MVV) (30 × base-
line forced expiratory volume in 1 s [FEV1]) for six minutes. 
The gas composed of 21% O2, 5% CO2, and 74% N to prevent 
syncope. Expired air passed through a dry- gas meter (Harvard 
Apparatus, Kent, UK) to measure minute ventilation (VE) and 
calculate percentage of MVV achieved (%MVV). Maximal 
flow- volume maneuvers were then completed in duplicate at 
3, 5, 7, 10, and 15 minutes post- EVH. An EVH challenge re-
sult was deemed positive (EIB- positive) if an athlete displayed 
a fall in FEV1 of ≥10% from baseline at two consecutive time- 
points,10 with the maximum change defined as ΔFEV1max. 
EIB severity was classified as: mild (≥10% but <25%), moder-
ate (≥25% but <50%), and severe (≥50%).9,25 To reverse bron-
choconstriction, EIB- positive athletes inhaled 200 μg or 400 μg 
salbutamol depending on EIB severity and performed maximal 
flow- volume maneuvers 10 minutes post- inhalation.
2.3 | EIB therapy
EIB- positive swimmers were prescribed pharmacological 
therapy by the team physician. Treatment was guided by 
EIB severity in a stepwise approach and within World Anti- 
Doping Agency regulations.9,25,29
2.4 | Follow- up assessment
Twelve months after the initial visit, athletes returned for a 
follow- up and completed the same respiratory assessments. 
Athletes diagnosed EIB- positive at the initial assessment 
were asked to continue using therapy as prescribed to evalu-
ate attenuation of EIB provided by pharmacological treat-
ment. Complete protection against EIB was defined as <10% 
ΔFEV1max at the follow- up assessment or clinical attenua-
tion if ΔFEV1max reduced by 50% compared to the initial 
test.1 Minimally important reduction in airway inflammation 
was defined as ≥20% reduction in FeNO (if >50 ppb), or a 
10 ppb reduction (if <50 ppb).26
EIB - negative athletes were required to adhere to the same 
criteria as at the initial test. EIB- negative athletes were re-
tested on the follow- up assessment as they were still reporting 
persistent respiratory symptoms or had a previous differential 
diagnosis of EIB.
2.5 | Data analysis
Athletes were retrospectively grouped according to whether 
they had arrived to the follow- up assessment using prescribed 
EIB therapy or not, as evaluated by a pre- assessment medical 
questionnaire. The groups were defined as: those who had 
arrived using EIB therapy (Therapy Adherent Group) and 
those who had discontinued therapy or were EIB- negative 
(Repeatability Group) (Figure 1).
2.6 | Statistical analysis
Data are presented as mean  ±  standard deviation unless 
stated. Normality was assessed through Shapiro- Wilk test. 
Differences between initial assessment and the follow- up 
assessment for main outcome measures (baseline spirom-
etry, FeNO and ΔFEV1max) were analyzed using paired- 
samples t test. The level of test- retest repeatability between 
“Repeatability Group” assessments was expressed as mean 
bias with 95% limits of agreement (LOA) and interpreted by 
Bland- Altman plot. Proportional bias was analyzed using lin-
ear regression. Correlation between “Repeatability Group” 
assessments was calculated using Pearson's correlation coef-
ficient (rp). Significance level was set at P ≤ .05 for all analy-
sis and performed using statistical package SPSS (SPSS v25, 
IBM, New York, USA).
3 |  RESULTS
3.1 | Participant characteristics
Twenty- seven elite swimmers, competing regularly at inter-
national level, were included in this retrospective data analy-
sis of comprehensive respiratory assessments (Table 1). Prior 
to the initial assessment, twelve athletes (44%) self- reported 
a history of asthma or EIB, and thirteen (48%) reported al-
lergenic environments worsened their respiratory symptoms. 
No athlete had evidence of significant airflow obstruction 
at baseline (ie, FEV1 >80% predicted & FEV1/FVC >70%; 
Tables 2 and 3).
From the initial assessment, twenty- three athletes (85%) 
were diagnosed as EIB- positive. At the time of the follow- up 
assessment, all EIB- positive athletes were prescribed SABA 
therapy for emergency use. All EIB- positive athletes were 
also prescribed a form of maintenance therapy, with eleven 
(48%) using daily ICS monotherapy, and twelve (52%) re-
quiring a combination of ICS and LABA therapy. In addi-
tion, two (9%) were prescribed add- on LTRA therapy. The 
remaining four EIB- negative athletes were not prescribed any 
treatment for EIB.
3.2 | Therapy adherent group
Twelve EIB- positive athletes returned to the follow- up 
assessment having used prescribed therapy as instructed 
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(Therapy Adherent Group). No athlete reported acute use 
of SABA therapy on the day of the follow- up assessment. 
Baseline FEV1 was significantly higher at the follow- up as-
sessment compared to initial assessment (P = .04; Table 2). 
The group magnitude of change in baseline FEV1 was 
240 mL (±356 mL), with individual responses presented in 
Fig. S1. On a group level, FeNO was not significantly dif-
ferent between assessments (P =  .07; Table 2). However, 
five athletes (42%) demonstrated a minimally important 
reduction in FeNO following use of therapy. Individual 
FeNO responses are presented in Fig.  S2. Minute venti-
lation (VE) during the EVH was not significantly differ-
ent between assessments (P =  .40); however, the %MVV 
achieved was significantly different (P  =  .04; Table  2). 
ΔFEV1max was significantly lower at the follow- up as-
sessment (−11.8  ±  3.8%) compared to the initial assess-
ment (−24.0 ± 11.3%) (P < .01; Table 2; Figure 2). Use of 
therapy afforded complete protection to four athletes (33%) 
and provided clinical attenuation to a further four athletes 
(33%).
3.3 | Test- retest repeatability
Eleven EIB- positive athletes arrived to the follow- up as-
sessment having discontinued EIB therapy (Repeatability 
Group). This group also included four EIB- negative ath-
letes (total n = 15). Baseline pulmonary function, FeNO, 
VE, and %MVV achieved did not differ significantly be-
tween assessments (P > .05; Table 3). There was no signif-
icant difference in ΔFEV1max between initial assessment 
(−13.1 ± 4.5%) and follow- up assessment (−12.3 ± 5.6%; 
P  =  .32). Individual ΔFEV1max responses are shown in 
Figure 3. Bland- Altman analysis indicated acceptable test- 
retest repeatability. The mean bias between assessments 
was 0.6% (95% LOA = −5.9, 7.1), with no data points out-
side the LOA (Figure 4). Linear regression analysis deter-
mined there was no proportional bias, as the distribution 
of agreement was not dependent on FEV1max (P =  .61). 
There was a statistically significant strong correlation 
in ΔFEV1max between assessments (rp  =0.81, P  <  .01; 
Figure 5).
F I G U R E  1  Schematic of retrospective data analysis. EIB, exercise- induced bronchoconstriction






Body mass (kg) 71.3 ± 8.7
Swimming training history (yrs) 11 ± 3
Weekly pool training volume (hrs) 23 ± 4
Note: Pooled data across both groups. Data presented as mean ± standard 
deviation.
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4 |  DISCUSSION
The present study is the first to report that a follow- up assess-
ment utilizing EVH can be useful in the long- term manage-
ment of EIB in elite swimmers. Our data from longitudinal 
respiratory assessments indicate that elite swimmers with EIB 
who maintain use of pharmacological therapy demonstrate 
improved pulmonary function at baseline, and attenuation of 
EIB induced by hyperpnea. We also demonstrated that elite 
swimmers who discontinue EIB therapy have a repeatable 
EVH challenge result after 12 months.
T A B L E  2  Therapy adherent group (total n = 12: males n = 7, 
females n = 5 )— baseline pulmonary function and EVH outcomes
Measure
Initial 
assessment Follow- up P- value
FEV1 (L) 4.60 ± 0.68 4.84 ± 0.77 0.04*
FEV1 (% of 
predicted)
110.2 ± 12.8 115.6 ± 15.3 0.03*
FVC (L) 5.98 ± 1.10 6.19 ± 1.10 0.07
FVC (% of 
predicted)
121.3 ± 14.0 124.3 ± 12.8 0.17
FEV1/FVC (%) 77.6 ± 6.5 79.08 ± 8.3 0.17
Baseline FeNO 33.7 ± 23.2 22.2 ± 17.2 0.07
ΔFEV1max (%) - 24.0 ± 11.3 - 11.8 ± 3.8 <0.01*







Note: Data presented as mean ±standard deviation.
Abbreviations: %MVV, percentage of maximum voluntary ventilation; FeNO, 
fraction of exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; VE, minute ventilation; ΔFEV1max, maximum fall in 
FEV1 from baseline following eucapnic voluntary hyperpnea (EVH) challenge.
*Statistically significant difference between assessments (P ≤ .05).
T A B L E  3  Repeatability group (total n = 15: males n = 7, females 
n = 8 )— baseline pulmonary function and EVH outcomes
Measure
Initial 


















Baseline FeNO 21.6 ± 13.7 24.5 ± 11.4 0.98








Note: Data presented as mean ±standard deviation.
Abbreviations: %MVV, percentage of maximum voluntary ventilation; FeNO, 
Fraction of exhaled nitric oxide; FEV1, Forced expiratory volume in 1 second; 
FVC, Forced vital capacity; VE, Minute ventilation; ΔFEV1max, Maximum 
fall in FEV1 from baseline following eucapnic voluntary hyperpnea (EVH) 
challenge.
*Statistically significant difference between assessments (P ≤ .05).
F I G U R E  2  Individual ΔFEV1max response in “Therapy 
Adherent Group.” Solid line denotes inhaled corticosteroid (ICS) 
treatment only, broken line denotes ICS combined with long- acting 
β2- agonist (LABA). Dotted horizontal line denotes 10% fall in FEV1 
diagnostic threshold. * Statistically significant difference between 
time- points P ≤ .05. FEV1, forced expiratory volume in 1 s; EIB, 
exercise- induced bronchoconstriction
F I G U R E  3  Individual ΔFEV1max response in “Repeatability 
Group.” [ ○ = EIB- negative ● = EIB- positive]. Broken horizontal 
line denotes 10% fall in FEV1 diagnostic threshold. FEV1, forced 
expiratory volume in 1 s; EIB, exercise- induced bronchoconstriction
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4.1 | Monitoring treatment
EIB management is achieved primarily through pharmaco-
logical intervention, with expert opinion driving the treat-
ment of elite athletes.30 Previous research has used EVH 
to objectively evaluate bronchial response following spe-
cific pharmacological treatments. In acute doses, 1500  μg 
beclomethasone,15 10  mg montelukast,16 0.5  mg terbuta-
line,14,17 and 40  mg sodium cromoglycate 18 all reduced 
bronchoconstriction induced by EVH. Our results demon-
strate that EVH is an effective tool to monitor the efficacy 
of long- term individualized pharmacological therapy in an 
elite swimming population, whom are uniquely exposed to 
additional chlorination by- products that EVH does not or-
dinarily induce.3,6,20 As presented in previous literature, 
a standard EVH has greater sensitivity than a chlorinated 
inspirate- modified EVH, and also a field- based swimming 
exercise challenge.20 Therefore, a standard EVH may be bet-
ter suited to monitor therapy efficacy, especially if used to 
confirm the initial diagnosis.
There is a distinct lack of literature evaluating pharma-
cological therapy providing attenuation of bronchoconstric-
tion in elite athletes with EIB. Similarly to the present study, 
Jackson et al12 demonstrated reduced EIB severity following 
nine weeks use of pharmacological therapy in elite football 
players. However, the present study is the first to demonstrate 
reduced EIB severity following twelve- month use of pharma-
cological therapy in an applied elite athlete population. The 
ability to effectively monitor EIB therapy is vital for athlete 
health, as it has been suggested that there is an association 
between uncontrolled EIB and predisposition to an athlete 
developing respiratory tract infection (RTI),31,32 which is 
reported to be a large burden on elite sport.33 In addition, 
effective maintenance therapy management can reduce the 
frequency of SABA use, reduce the risk of tachyphylaxis de-
velopment,34 and respiratory condition exacerbation.35
Adherence to maintenance therapy provided complete 
protection to four athletes (33%), but provided clinical at-
tenuation to a further four athletes (33%). Thus, eight (66%) 
of our adherent cohort demonstrated substantial reduction in 
EIB severity. Unfortunately, it is not possible to determine 
whether EIB attenuation is solely the result of long- term 
maintenance therapy, or by a dose administered by the athlete 
on the morning of the follow- up assessment (ie, this same 
effect would also be evident in acute use of ICS/LABA). 
Athletes using ICS/LABA combined therapy demonstrated 
the greatest reduction in EIB severity (Figure 1). However, 
one athlete using ICS monotherapy showed a substantial re-
duction in EIB severity (−25% to −10% ΔFEV1max). The 
magnitude of EIB protection afforded by acute vs long- term 
use of maintenance therapy should be investigated further. 
In addition, as not all athletes showed reduction in EIB se-
verity post- treatment, future studies should investigate how 
attenuation can be enhanced in athletes who do not respond 
adequately to standard treatment.
4.2 | Improvement in baseline FEV1
The present study showed a mean increase of 240  mL in 
baseline FEV1 following long- term use of pharmacological 
maintenance therapy. To our knowledge, this is the first time 
this has been published in an elite athlete population, who al-
ready possess high baseline pulmonary function.13 A change 
in FEV1 of >200 mL would be considered minimal clinically 
important.36 Our relative magnitude of change in baseline 
F I G U R E  4  Bland- Altman plot for test- retest repeatability of 
maximum reduction in FEV1 (ΔFEV1max) between EVH assessments. 
[○ = EIB- negative ● = EIB- positive]. Broken horizontal line 
denotes mean bias, dotted lines indicate 95% upper and lower limits 
of agreement. FEV1, forced expiratory volume in 1 s; EVH, Eucapnic 
voluntary hyperpnea; EIB, exercise- induced bronchoconstriction
F I G U R E  5  Correlation of maximum reduction in FEV1 
(ΔFEV1max) between EVH assessment visits. [ ○ = EIB- negative 
● = EIB- positive]. Broken horizontal and vertical lines denote 10% 
fall in FEV1 diagnostic threshold. Solid line indicates line of equality, 
dotted line denotes dataset line of best fit. FEV1, forced expiratory 
volume in 1 s; EVH, Eucapnic voluntary hyperpnea; EIB, exercise- 
induced bronchoconstriction
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FEV1 (↑ of 5%) was similarly presented by Simpson et al,
17 
who in a cohort of recreationally active athletes showed a 
smaller (but statistically significant) bronchodilator effect 
following acute 0.5 mg terbutaline (mean increase of 170 mL 
(↑ of 5%)). This finding was further enhanced to 194  mL 
when a larger cohort was later included in their analysis.14 
Eight of our adherent group were prescribed a LABA in 
combination with ICS. The inclusion of LABA therapy may 
have contributed to an increase in baseline FEV1, as the larg-
est magnitude of change came from those using concurrent 
therapy, rather than ICS alone (Fig. S1). Even though athletes 
would have been prescribed a SABA as needed, no athlete 
reported acute use of this prior to the follow- up assessment, 
suggesting the increase in baseline FEV1 came from main-
tenance therapy (ie, ICS or ICS/LABA combined therapy). 
However, as previously stated, it is difficult to distinguish if 
this observation would also be evident in acute use of ICS/
LABA maintenance therapy.
4.3 | Fraction of exhaled nitric oxide
Airway inflammation related to “clinical” asthma has been 
shown to reduce following regular use of ICS in the general 
population.37 One would therefore expect this to occur in ath-
letes with EIB actively using ICS, as has previously been re-
ported in a cohort of elite footballers.12 Despite no significant 
group effect in our cohort, five athletes (42%) did display a 
minimally important reduction in airway inflammation fol-
lowing adherent use of maintenance therapy.
EIB pathophysiology is heterogeneous in nature. Most 
notably, EIB is thought to present in two main phenotypes; 
atopic, and those without allergic features.38 It is evident 
that six of our adherent athletes (50%) may fall into the lat-
ter group, displaying “normal” levels of FeNO at the initial 
assessment (Fig. S2). With inherently low levels of FeNO, 
these athletes would have affected the statistics at a group 
level. These findings provide further evidence of an individ-
ualized inflammatory profile associated with EIB, as such, 
FeNO could be useful in selected athletes to support the di-
agnosis of EIB 26 and monitor efficacy of pharmacological 
therapy. It may be appropriate to use FeNO in combination 
with other intermediate respiratory assessments (ie, monitor-
ing of respiratory symptoms, pulmonary function at baseline 
and following exercise) once treatment has been initiated, es-
pecially in athletes who do not present allergic features.
4.4 | Test- retest repeatability of EVH
The present study showed good long- term test- retest repeat-
ability of EVH in a cohort of elite swimmers. Good test- retest 
repeatability is essential for an assessment to be used as a 
clinical utility,21 particularly over a long time period. These 
findings support previous research demonstrating that EVH 
produces repeatable results on a short 22- 24 and medium- term 
24 basis. The findings of the present study are consistent with 
a previous investigation on elite swimmers, where the au-
thors demonstrated strong correlation between repeated EVH 
challenges, and good test- retest repeatability, albeit over a 
short time period (~1 day).23 Moreover, the mean bias (0.7%) 
and LOA (~6%) reported by Stadelmann et al 23 were simi-
lar to our study. Medium- term (≤70 days) repeatability has 
been demonstrated previously in physically active individu-
als with EIB.24
In the present study, EIB- positive elite swimmers pro-
duced repeatable results, including those with mild EIB 
severity. Our results support findings by Williams and col-
leagues,24 who reported reproducible ΔFEV1max irrespec-
tive of EIB severity. However, Price et al 39 demonstrated 
wider limits of agreement in a cohort of recreationally ac-
tive individuals, particularly those with a mild or borderline 
response. This inconsistency in literature may be due to the 
population investigated, and the severity of EIB within the 
group. The comparable low mean ΔFEV1max (10  ±  8%), 
small cohort of physician- diagnosed asthmatics, and a non- 
elite athletic population may have contributed to wider lim-
its of agreement seen by Price et al39 It has previously been 
suggested that using EVH with elite athletes is more suitable 
than with recreationally active individuals, due to the abil-
ity to maintain high- ventilation rates and the stimulus closer 
mimics the demands of high- intensity exercise, at which elite 
athletes are more accustomed.8 Moreover, as previously dis-
cussed, the heterogenous phenotypes of EIB may impact how 
EIB develops in recreational compared to elite athletes.
4.5 | Adherence
A pertinent observation of the present study is that cessa-
tion of therapy was high within our cohort, with eleven (48% 
of EIB- positive athletes) returning to the follow- up assess-
ment having ceased treatment. However, our respiratory as-
sessments were completed following a periodized recovery 
mesocycle, so it was often anecdotally reported that athletes 
had stopped EIB therapy due to cessation of training and 
competition, suggesting symptoms that normally would be 
present had reduced, thus negating the perceived requirement 
for therapy. It is likely that EIB- positive athletes within our 
“repeatability group” deployed an “on- off” relationship with 
therapy throughout the twelve- month period. The reasons as 
to why an individual adheres (or not) to therapy will be mul-
tifactorial, and further emphasizes the challenge of manag-
ing chronic medical conditions in elite athletes. We hope our 
findings highlight the need to investigate strategies aimed at 
improving adherence to therapy in elite athletes diagnosed 
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with asthma and/or EIB. Such interventions may incorporate 
athlete/coach education, closer monitoring of inhaler use by 
team physician, and more regular appraisal of respiratory 
symptoms.
4.6 | Limitations
The long- term monitoring of elite swimmers over a twelve- 
month period has valid strengths; including avoiding sea-
sonal variation, and a consistent pre- season training state at 
each assessment. An elite performance environment is inher-
ently time restricted due to volume of training and competi-
tion. Therefore, it can be troublesome to obtain access to this 
population for initial consultation, but more so for a follow-
 up assessment to investigate the response to a treatment.
A key limitation of this study is the retrospective, rather 
than prospective nature of the experimental design. More 
specifically, the athletes were not studied in a randomized 
double- blinded placebo- controlled manner, and thus our re-
sults must be interpreted with this in mind. In addition, we 
were not able to report or quantify exactly when therapy was 
used during the twelve- month period before the follow- up as-
sessment (ie, athletes may have only ceased or recommenced 
therapy in the weeks preceding the scheduled follow- up, or 
not maintained therapy religiously over the twelve- month 
duration). The implication of this is it can take up to four 
weeks following the initiation of maintenance therapy to see 
maximal protection, particularly in outcome measures such 
as FeNO.9
Within our study, we were not able to conduct assess-
ments of swimming performance alongside monitoring air-
way health. An important driving factor in elite sport is the 
impact of a medical condition or intervention on exercise 
performance. At present, the effect of treated and untreated 
EIB on overall health and exercise performance remains 
largely unknown.40 While it is difficult to demonstrate the 
effect of uncontrolled EIB on exercise performance, attempts 
have been made to investigate the impact of EIB detection 
and treatment; however, samples are often small and results 
inconclusive.12,41 This clearly warrants further investigation 
from both a health and anti- doping standpoint.
5 |  PERSPECTIVE
The results of the present study provide support for EVH as 
a clinical utility to evaluate the efficacy of pharmacological 
EIB therapy. Moreover, the findings suggest that EVH chal-
lenges are repeatable over a twelve- month period in an elite 
swimming population. While not advocating the frequent 
use of EVH, our results demonstrate that a follow- up assess-
ment after treatment initiation can be beneficial. Follow- up 
assessments provide an opportunity to ensure EIB therapy 
is adequate, reinforce inhaler technique, emphasize impor-
tance of adherence, and assist education to athletes / support 
staff.9 Once treatment is deemed to provide clinical attenua-
tion for EIB, intermediate baseline respiratory assessments 
(ie pulmonary function, FeNO and respiratory health ques-
tionnaires) could be implemented, unless an alteration in 
EIB therapy occurs or there is an emergence of respiratory 
symptoms.
As proposed by Hull et al,33 our research supports a so- 
called “systematic approach to respiratory athlete health” 
(SARAH) to enhance the identification and management 
of respiratory disorders, such as EIB, exercise- induced la-
ryngeal obstruction, dysfunctional breathing,42 and RTI.32 
Failure to optimize respiratory care presents a risk of respi-
ratory condition exacerbation, and subsequent reduction in 
exercise performance and/or health.
6 |  CONCLUSION
Overall, this study provides evidence that a follow- up as-
sessment incorporating EVH can be suitable to monitor the 
efficacy of pharmacological EIB therapy in an elite swim-
ming population. Active use of appropriately prescribed 
therapy increased baseline FEV1 and reduced EIB severity. 
Furthermore, EVH demonstrated good test- retest repeatabil-
ity over a twelve- month period in elite swimmers who had 
discontinued EIB therapy, or were EIB- negative.
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